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Abstract
Background: Maternal and fetal Low Density Lipoprotein-Cholesterol (LDL-C) concentrations are compromised in
intrauterine growth restriction (IUGR). Generally, LDL-C catabolism is under control of PCSK9 by binding to the
LDL-receptor leading to its degradation. Hence, we hypothesized a role for PCSK9 in the modulation of lipid
metabolism and placental transport in IUGR.
Methods: 172 women, 70 IUGR and 102 controls were included in the study. Maternal and fetal serum PCSK9 levels
and lipid profiles including LDL-C were measured. Placental LDL-receptor and PCSK9 expressions were estimated by
tissue microarray immunohistochemistry, and analyzed by two blinded observers using an immunoreactivity score.
Non-parametric tests and multivariate regression analyses were used for statistical estimations.
Results: PCSK9 levels in the maternal and fetal compartment independently predicted LDL-C levels (maternal
compartment: adjusted R2 = 0.2526; coefficient bi = 0.0938, standard error sbi =0.0217, rpartial = 0.4420, t-value = 4.323,
p < 0.0001; fetal compartment: adjusted R2 = 0.2929; bi = 0.1156, sbi =0.020, rpartial = 0.5494, t-value = 5.81, p < 0.0001).
We did not find significant differences in maternal PCSK9 concentrations between IUGR and controls. However, we
found lower fetal serum PCSK9 concentrations in IUGR than in controls (IUGR median 137.1 ng/mL (95% CI 94.8-160.0)
vs. controls 176.8 (154.6-202.5), p = 0.0005). When subgrouping according to early onset, late onset IUGR, and fetal
gender differences remained consistent only for male neonates born before 34 weeks of gestation. In the placenta
we found no correlation between PCSK9 and LDL-receptor expression patterns. However, the LDL-receptor was
significantly upregulated in IUGR when compared to controls (p = 0.0063).
Conclusions: Our results suggest that PCSK9 play a role in impaired fetal growth by controlling fetal LDL-C
metabolism, which seems to be dependent on gestational age and fetal gender. This underlines the need
to identify subgroups of IUGR that may benefit from individualized and gender-specific pharmacotherapy
in future studies.
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Background
Pregnancy is associated with immense changes in lipid
metabolism. Maternal blood concentration levels of the
predominant cholesterol transport vehicles, the Low-
Density Lipoproteins (LDL), increase by about 70% from
first to third trimester [1]. As a precursor of steroid
hormones the placenta requires LDL-Cholesterol (LDL-
C) for the synthesis of progesterone [2]. Moreover, chol-
esterol is an essential component for placental and fetal
development, and it is estimated that 20 to 50% of fetal
cholesterol originates from the mother by active trans-
placental cholesterol transport [3, 4]. The uptake of LDL
by the placenta is well described and particularly
involves the LDL-receptor (LDLR) [3].
Compromised fetal development occurs in 3 to 8% of
all pregnancies, and is associated with increased peri-
natal morbidity and mortality because of fetal hypoxia or
iatrogenic preterm delivery [5].
Recently, we reported corresponding to the results of
others that intrauterine growth restriction (IUGR) is
linked to a disturbed cholesterol metabolism associated
with lower LDL-C concentrations in maternal and fetal
blood [6–9]. The mechanisms regulating cholesterol
homeostasis during pregnancy and under pathological
conditions such as IUGR are not fully understood.
Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9)
is a serine protease secreted as a glycoprotein into the
circulation. Since its discovery in 2003 PCSK9 has
emerged as a significant modulator of LDL metabolism
[10, 11]. Loss of function mutations of PCSK9 are associ-
ated with low plasma LDL-C levels [12, 13]. The mode of
action of PCSK9 is its binding to the LDLR subsequently
leading to internalization and degradation of the receptor
[14]. As a consequence the reduced number of LDLR on
the cell surface leads to lower LDL turnover rates and
higher circulating LDL-C concentrations [15]. The inhib-
ition of the mechanism lowers LDL-C levels, and this has
led to the development of PCSK9 inhibitors like evolocu-
mab which have been approved for the treatment of
hypercholesterolemia in 2015 when statine therapy fails.
Recent studies confirmed the presence of PCSK9 in
maternal and umbilical cord blood as well as in the
placenta [16–18]. Indeed, concentration levels of PCSK9
were higher in pregnant women at term than in non-
pregnant women suggesting a potential role in control-
ling cholesterol homeostasis during pregnancy [17].
Since LDL metabolism is disturbed in IUGR we hypoth-
esized that PCSK9 is involved in the regulation of LDL
distribution throughout different compartments (mater-
nal, placental, and fetal) and that it contributes to the
pathogenesis of IUGR by affecting transplacental choles-
terol transport. Because therapeutic options already exist,
the PCSK9/LDL metabolism seemed a promising pathway
to be studied in pregnancy pathologies.
Methods
It was the aim of the present study to compare PCSK9
levels in maternal and fetal blood of pregnancies compli-
cated by IUGR and uncomplicated pregnancies, and to
investigate the expression patterns of PCSK9 and its
ligand, the LDLR, in the placenta. Hence, biomaterial for
this case-control study was sampled prospectively taking
into account the three different compartments of the
materno-placento-fetal unit. Prior to the study, a power
analysis was performed by calculating the minimal
required sample size on the basis of the maternal
LDL-C/High Density Lipoprotein-Cholesterol (HDL-C)
ratio. Choosing a power (1–β-error) of 80% and a level of
significance (α-error) below 0.05 for each group, IUGR
and CTRL, at least 26 patients had to be included [7].
Study cohort
Biomaterial was sampled at the Department of
Obstetrics and Gynecology, University Hospital of the
RWTH Aachen between July 2006 and March 2012
as described [19–21].
Clinical data were recorded at inclusion and following
delivery. Gestational age was calculated by the last
menstrual period and verified by first trimester scan
documentation as described [7]. Maternal blood was
taken after 24 weeks of gestation and prior to delivery.
Fetal cord blood and placental tissue were sampled
immediately after birth.
172 individual patients were selected. Of those 70
patients were classified as IUGR and 102 served as con-
trols (CTRL) with adequate growth and birthweight
between 10th and 90th percentile. In 54 patients of the
IUGR group iatrogenic delivery was performed preterm
before 37th week of gestation because of non-reassuring
fetal wellbeing. 51 patients of the CTRL group delivered
preterm because of onset of spontaneous preterm deliv-
ery or premature rupture of the membranes. Important
clinical characteristics include maternal age, BMI, blood
pressure, fetal birth weight, and birth weight centiles
(Table 1). Maternal lipid profile including LDL-C, HDL-C,
total cholesterol (TC) and triglyceride (TG) values were
available in 99 patients of the CTRL group and in 70
patients of the IUGR group. Fetal lipid profile was
measured in 76 CTRL and 54 IUGR cases. Fetal and
neonatal birth weight centiles were determined according
to the population-based, newborn weight charts [22].
Additionally, customized centiles were calculated by the
use of the online platform www.gestation.net (Gardosi J,
Francis A. Customised weight centile calculator. GROWTH
V6.7.6.11 (DE)).
IUGR was defined in accordance to the ACOG guide-
lines as described recently [5, 7]. In addition to having
an estimated fetal weight below the 10th centile, one of
the following criteria had to be fulfilled: (i) deceleration
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of fetal growth velocity during the last 4 weeks, (ii)
elevated resistance index in umbilical artery Doppler
sonography above the 95th percentile or absent or
reversed end-diastolic blood flow (ARED), (iii) fetal
asymmetry (head to abdominal circumference ratio
above the 95th percentile), or (iv) oligohydramnios (am-
niotic fluid index <6 cm). Patients were further sub-
grouped into early onset (before 34 weeks) and late
onset (after 34 weeks) phenotype of IUGR [23, 24].
Exclusion criteria were the following: multiple gesta-
tion, fetal anomalies, abnormal fetal karyotype, patients
with clinical or biochemical signs of infection, positive
TORCH screening results, maternal diabetes mellitus/
gestational diabetes or other severe maternal metabolic
disorders, as well as patient’s withdrawal from the study.
Blood sampling, serum generation and storage of
aliquots
Blood samples were taken using Monovette syringes
(Serum 4.9 mL Monovette, Sarstedt, Germany). After
incubation at room temperature for 15–30 min, samples
were centrifuged at 2000 g for 15 min. Serum was ali-
quoted and stored at −80 °C.
Basic serum lipid profiling
TG, TC, LDL- and HDL-C levels were measured by
colorimetric enzymatic methods using an automated
photometric measuring unit (Roche/Hitachi Modular
P800, Roche Diagnostics, Basel, Switzerland) as de-
scribed [7].
Enzyme Linked Immunosorbant Assay (ELISA)
PCSK9 concentrations were determined by enzyme linked
immunosorbent assays (ELISA) (Biorbyt, Cambridge, UK)
in duplicates according to the manufacturer’s protocol.
Placental sampling, tissue microarrays and
immunohistochemistry
Random pieces of the intermediate third of the placenta
were chosen from vital cotyledons that were macroscop-
ically free of infarct areas or other obvious morphologic
pathologies immediately after delivery. Processing and
Table 1 Maternal and neonatal clinical characteristics and lipid concentrations
CTRL IUGR P
n Mean or % 95% CI n Mean or % 95% CI
maternal age (y) 102 31.9 30.7–33.0 70 29.6 28.1–31.2 0.0193
maternal hight (m) 102 1.67 1.66–1.69 70 1.66 1.64–1.67 0.0878
maternal pre-pregnancy weight (kg) 102 66.4 63.3–69.5 70 67.6 63.5–71.6 0.6388
maternal pre-pregnancy BMI (kg/m2) 102 23.7 22.7–24.6 70 24.5 23.2–25.8 0.2686
maternal parity 102 0.95 0.75–1.16 70 0.64 0.37–0.91 0.0682
maternal smoking status (%) 102 20 12.0–27.0 70 36 24.0–47.0 0.0181
maternal pre-pregnancy smoking status (%) 102 39 30.0–49.0 70 47 35.0–59.0 0.3042
maternal systolic blood pressure (mmHg) 102 117 114.6–119.0 70 127 122.7–131.9 0.0000
maternal diastolic blood pressure (mmHg) 102 67 64.9–68.5 70 76 72.2–78.8 0.0000
hypertension in pregnancy (%) 102 0 0.0–0.0 70 27.0 16.0–38.0 0.0000
gestational age at inclusion 102 32.2 31.2–33.1 70 31.6 30.5–32.6 0.4053
delivery week of gestation (w) 102 35.3 34.4–36.2 70 32.7 31.7–33.7 0.0002
neonatal gender (% female) 102 49 39.0–58.9 70 46 34.0–58.0 0.6720
neonatal weight at birth (g) 102 2559 2376–2743 70 1347 1192–1502 0.0000
neonatal birth weight centile (population based) 102 43.7 39.8–47.6 70 4.1 3.5–4.8 0.0000
neonatal birth weight centile (customized) 102 43.1 38.2–48.0 70 0.7 0.2–1.1 0.0000
maternal LDL cholesterol (mg/dL) 99 152.5 144.6–160.5 70 125.5 114.6–136.4 0.0001
maternal HDL cholesterol (mg/dL) 99 75.6 72.1–79.1 70 71.9 67.88–75.92 0.1694
maternal total cholesterol (mg/dL) 99 268.6 258.6–278.7 70 235.6 222.6–248.6 0.0001
maternal triglycerides (mg/dL) 99 238.3 216.7–259.9 70 214.4 189.5–239.3 0.1525
fetal LDL cholesterol (mg/dL) 76 28.5 25.1–31.9 54 20.54 17.01–24.06 0.0018
fetal HDL cholesterol (mg/dL) 76 31.0 28.9–33.0 54 15.81 13.84–17.79 0.0000
fetal total cholesterol (mg/dL) 77 70.1 65.4–74.9 54 50.78 46.37–55.18 0.0000
fetal triglycerides (mg/dL) 77 22.4 19.6–25.1 54 45.19 37.65–52.72 0.0000
P-values are in bold if considered significant (<0.05)
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paraffinisation was done according to a standardized
protocol as described [21]. Of each individual patient
three placental tissue samples were then rearranged in
tissue microarray paraffin blocks achieving a total of 40
IUGR and 40 gestational age matched CTRL triplicates.
Immunohistochemistry was performed as previously de-
scribed [21, 25] using polyclonal goat anti-human
PCSK9 (1:40), and monoclonal mouse anti-human LDLR
(1:400) antibody (Novus, Littleton, CO). Sections were
counterstained with hematoxylin. Control reactions ex-
cluding the use of primary antibodies did not reveal any
staining. A positive control was done using human hep-
atic tissue. Two blinded observers (BB and IL) selected
the central high power field (1:400) of each placental tis-
sue spot using an All-in-one Microscope Modell BZ-
9000E HS (Keyence, Osaka, Japan) equipped with a BZ-
H2AE Image Analyzer. Evaluation of staining pattern
and intensity were performed using immunoreactivity
score (IRS) separately for trophoblasts and endothelial
cells. Interobserver variability was below 10%.
Statistics
nQuery Advisor 7.0 (Janet D. Elashoff (2007), CA, USA)
was used for sample size calculation. Data analysis was
carried out using the statistical packages Prism Version
6.0e Software (GraphPad Software Inc., CA, USA). Clin-
ical data are presented as means ± 95% CI. Analytical
variables are expressed as median ± 95% CI. Two-tailed
Mann-Whitney-Test was conducted for comparison of
metric variables. Fisher’s exact test was used for categor-
ical data. Correlations were analyzed by Spearman’s
correlation coefficient. Values of p < 0.05 were regarded
as significant. Stepwise multivariate linear regression
analyses were performed to assess the association be-
tween serum levels of PCSK9 and LDL-C, and gesta-
tional age at sampling and delivery, fetal gender, and
study-group. Logistic regression analysis was performed
to estimate the predictive value of PCSK9 and LDL-C on
the diagnosis of IUGR using MedCalc® V9.4.2.0. The var-
iables with a p-value < 0.1 on univariate analysis were en-
tered into multivariate models.
Results
Clinical characteristics and lipid profiles of the study
cohort
Maternal and neonatal characteristics are summarized in
Table 1. Maternal age and smoking status during preg-
nancy differed slightly between the study groups while
pre-pregnancy BMI, parity, gestational age at inclusion
into the study, and neonatal gender were kept similar.
None of the CTRL group and 19 women (27%) in the
IUGR group were hypertensive during pregnancy. Gesta-
tional age at delivery was kept similar in patients in which
placenta (CTRL mean 32.5 weeks (95% CI 31.2–33.8) vs.
IUGR 32.0 (30.8–33.1)) and/or fetal cord blood (CTRL
mean 34.2 weeks (95% CI 32.9–35.5) vs. IUGR 34.0 (32.7–
35.3)) had been analyzed. For analyzes of maternal blood,
only those patients were included in the CTRL group who
delivered a healthy neonate after 37 weeks of gestation to
avoid masking pathologic conditions (weeks of gestation
at sampling: CTRL mean 31.5 weeks (95% CI 30.0–33.0)
vs. IUGR 31.1 (29.7–32.6), weeks of gestation at birth:
CTRL mean 38.8 weeks (95% CI 38.3–39.3) vs. IUGR 31.8
(30.4–33.3)). Mean maternal LDL-C concentration was
18% lower in IUGR as compared to CTRL. Mean TC
concentration was 12% lower. In the fetal compartment
LDL-C and TC concentrations were lower by 28% in
IUGR as compared to CTRL (Table 1).
PCSK9 in the maternal compartment
PCSK9 concentrations in maternal blood were twice as
high as in the fetal blood (Fig. 1a). Within the CTRL
group PCSK9 concentration levels were positively asso-
ciated with gestational age at sampling (Fig. 2a). How-
ever, LDL-C levels in the CTRL group remained
remarkably constant from 24 weeks of gestation onward
until term, while increasing LDL-C levels could be
observed in the IUGR group (Fig. 2b).
There were no significant differences in maternal
PCSK9 serum concentrations between IUGR and CTRL
(Fig. 1a). Multivariate regression analyses revealed that
both, maternal PCSK9 levels and the study group ‘IUGR’
independently predicted maternal LDL-C levels
(adjusted R2 = 0.2526; PCSK9 coefficient bi = 0.0938,
standard error sbi = 0.0217, rpartial = 0.4420, t-value = 4.323,
p < 0.0001, IUGR coefficient bi = −28.7631, standard error
sbi =8.8658, rpartial = −0.3468, t-value = −3.244, p < 0.0017).
Adjustment for other clinical characteristics like maternal
age, BMI, and smoking status, or gestational age did not
improve the predictive value. However, separate subgroup
analyses confirmed an association of PCSK9 and LDL-C
in the IUGR group but not in the CTRL group (Fig. 2c).
In a logistic regression analysis maternal LDL-C levels but
not PCSK9 remained an independent predictor for IUGR
(Odds Ratio = 0.985 (95% CI 0.974–0.996), p = 0.0086).
PCSK9 in the fetal compartment
In contrast to findings in the maternal compartment,
fetal PCSK9 and LDL-C concentration levels in the
CTRL group were negatively associated with gestational
age at delivery (Fig. 3a and b). Mean fetal PCSK9 con-
centration in IUGR was 35% lower than in CTRL
(Fig. 1a). The effect persisted when subgrouping into
early and late onset IUGR according to gestational age
at birth, e. g. neonates born between 24 and 34 weeks
versus those born after 34 weeks of gestation (Fig. 1c).
Further subgrouping according to fetal gender revealed
highest PCSK9 concentrations in male neonates of the
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CTRL group born before 34 weeks of gestation (Fig. 1d).
Significant differences between IUGR and CTRL remained
consistent only for this subgroup (Fig. 1d and e).
In multivariate regression analyses fetal PCSK9 levels
remained an independent predictor of fetal LDL-C con-
centrations (adjusted R2 = 0.2929; bi = 0.1156, sbi =0.020,
rpartial = 0.5494, t-value = 5.81, p < 0.0001). Adjustment
for other clinical characteristics like gestational age or
fetal gender did not increase the predictive value. Sub-
group analyses confirmed a positive association of
PCSK9 and LDL-C in both groups (Fig. 3c). In logistic
regression analysis fetal PCSK9 was predictive for IUGR
(Odds Ratio = 0.986 (95% CI 0.977–0.994), p = 0.0015).
Considering fetal LDL-C levels in the model did not im-
prove the predictive value.
Placental PCSK9 and LDLR expression patterns
Staining for PCSK9 was predominantly found in tropho-
blast (cytotrophoblast and syncytiotrophoblast) and
endothelial cells, and to a minor degree in villous stroma
cells (Fig. 4a). No differences have been found in PCSK9
expression patterns between IUGR and CTRL when









































































































































Fig. 1 a-e Maternal and fetal serum PCSK9 concentrations of IUGR and CTRL in gestational age and gender subgroups presented as Tukey’s box plots.
a Maternal and fetal PCSK9 concentration comparing IUGR and CTRL. b Maternal PCSK9 concentrations in IUGR and CTRL sampled between 24 and 34
versus after 34 weeks of gestation. c Fetal PSCK9 concentrations in IUGR and CTRL of those born between 24 and 34 versus after 34 weeks of
gestation. d-e Fetal PCSK9 concentrations grouped by gestational age at delivery (d) before and e) after 34 weeks of gestation) and fetal gender
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LDLR expression could be observed throughout all
compartments of the placenta, the trophoblast, pla-
cental stroma cells, and the endothelium (Fig. 4b).
LDLR expression was higher in the trophoblast layer
of IUGR as compared to CTRL placentas (Fig. 5b).
When subgrouping according to gestational age at
delivery the higher LDLR expression in IUGR consist-
ently could be found in placentas delivered after
34 weeks of gestation (Fig. 5e).
In correlation analyses LDLR expression in tropho-
blasts over all was tendentielly negatively associated with
maternal LDL-C (r = −0.22, p = 0.05), while LDLR
expression in endothelial cells was positively associated
with fetal LDL-C levels (r = 0.24, p = 0.036). No other
major associations have been observed between placen-
tal PCSK9 and LDLR expression patterns and clinical or
biochemical parameters, respectively.
Discussion
To the best of our knowledge this is the first analysis of
PSCK9 concentration and expression patterns in the
maternal, fetal, and placental compartment in a well-
defined IUGR cohort.
We confirmed lower LDL-C concentrations in mater-
nal and fetal blood in IUGR as compared to CTRL.
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Fig. 2 a-c Linear regression analyses to estimate the association
between maternal PCSK9 and LDL-C serum concentrations, and
gestational age at blood sampling. Displayed are regression lines
and 95% Confidence Intervals separately for the IUGR and the
CTRL group. a PCSK9 and gestational age, b) LDL-C and gestational
age, c) PCSK9 and LDL-C. WOG=week of gestation
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Fig. 3 a-c Linear regression analyses to estimate the association
between fetal PCSK9 and LDL-C serum concentrations, and gestational
age at delivery. Displayed are regression lines and 95% Confidence
Intervals separately for the IUGR and the CTRL group. a PCSK9 and
gestational age, b LDL-C and gestational age, c PCSK9 and LDL-C.
WOG=week of gestation
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PCSK9 independently predicted LDL-C concentration
levels in both compartments. However, while maternal
PCSK9 levels did not differ significantly between IUGR
and CTRL, we found significant lower concentration
levels of PCSK9 in umbilical cord blood of IUGR as
compared to the CTRL group, suggesting that independ-
ent regulatory metabolic pathways are activated in the
mother and in the fetus. In addition, the placenta as the
linking organ showed higher LDLR expression patterns
in IUGR when compared to CTRL while we found no
significant difference in PCSK9 expression.
Few studies have been performed to analyze PCSK9
expressions in pregnancy, so far. Interestingly, Peticca et
al. recently showed that PCSK9 did not correlate with
LDL-C levels in uncomplicated third-trimester pregnan-
cies. The physiological disruption of this association dur-
ing pregnancy suggests that, unlike in women in the
non-pregnant state, other effects are superior to PCSK9
in controlling maternal LDL-C levels [17]. The present
study partially confirmed their findings. Maternal PCSK9
levels were associated with LDL-C levels only in the
IUGR group but not in uncomplicated pregnancies. This
suggests an inadequate adaptation of maternal metabol-
ism in pregnancy when complicated by IUGR. The
placenta plays a crucial role in the pathogenesis of IUGR
and, as a main source of steroid hormones during preg-
nancy, is highly dependent on cholesterol supply [2].
Recently, Dubé et al. showed that mRNA and protein of
PCSK9 and its target protein LDLR is expressed in the
human placenta suggesting an impact of PCSK9 on the
regulation of placental LDL uptake [18]. We questioned
whether differences in the activation of metabolic path-
ways could be confirmed in the placenta of IUGR and
therefore analyzed expression patterns by immunohisto-
chemistry using tissue microarrays. This method allows
standardizing staining techniques and estimating expres-
sion patterns by directly comparing 80 individual
samples within a single slide. The advantage of immuno-
histochemistry over other techniques for protein expres-
sion determination is the possibility to estimate
cell-staining intensities in different compartments of the
placenta, e. g. the maternoplacental (trophoblast), and
the fetoplacental surface (endothelium) [21]. We could










Fig. 4 a-b Sample of a tissue microarray slide and representative high power field (×400) of A) PCSK9 and B) LDLR immunohistochemistry. Staining
patterns were similar in CTRL and IUGR. However, staining intensity was higher for the LDLR in IUGR (as shown in Fig. 5). CT = cytotrophoblast,
ST = syncytiotrophoblast, EC = endothelial cell
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PCSK9 in the trophoblast nor in the endothelium of
IUGR placentas when compared to CTRL. However, we
found a stronger expression of LDLR in trophoblasts of
IUGR than in CTRL placentas at least after 34 weeks of
gestation. This is in agreement with other publications.
Stepan et al. found LDLR mRNA expression to be
upregulated in IUGR placentas [26]. Wadsack et al. re-
ported a higher placental LDLR protein expression [9].
The authors suggested that compensatory mechanisms
to the lower maternal LDL concentration might be acti-
vated in order to guarantee fetal cholesterol supply.
Dubé et al. recently reported on lower maternal LDL-C
levels in pregnancies complicated by gestational diabetes
as compared to normal pregnancy. Yet, in their study
they found lower placental PCSK9 expression levels in
the diabetes group [18]. The contradiction to our results
may be explained by different methods (Dubé et al. used
western blot to quantify PCSK9 expression. This method
does not take into account differences in placental
morphology and composition between study groups) or
by different pathways being involved in the regulation of





























































































































































Fig. 5 a-f Placental (a) PCSK9 and (b) LDLR immunoreactivity score (IRS) for IUGR and CTRL presented as Tukey’s box plots separately for the
maternoplacental (trophoblast) and fetoplacental (endothelium) interface. Analyses were further performed for subgroups according to gestational age
at delivery (before and after 34 weeks of gestation), and separately for trophoblast (c) PCSK9, e) LDLR) and endothelium (d) PCSK9, f) LDLR)
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acts posttranscriptionally by degradation of the LDLR,
higher mRNA levels in IUGR placentas as observed by
Stepan et al. suggest a transcriptional regulation [26].
In the fetal compartment we found PCSK9 concentra-
tion levels positively associated with LDL-C levels which
is in agreement with the literature [16, 17]. In IUGR cir-
culating PCSK9 concentrations were lower when com-
pared to CTRL. Two other studies analyzed fetal cord
blood PCSK9 concentrations in small for gestational age
neonates (SGA). Neither of the studies found any differ-
ences in PCSK9 concentration levels between their SGA
and control groups [16, 17]. The terms ‘SGA’ and ‘IUGR’
are often used synonymeously which may lead to misin-
terpretation and may explain the mismatch to our re-
sults. Peticca et al. and Araki et al. defined SGA by birth
weight centile only. We recently pointed out that it is
mandatory to differentiate between constitutional SGA
and IUGR by specific antenatal sonographic criteria in
addition to an estimated low fetal weight [7, 19]. More-
over, it has been suggested to consider two different
phenotypes when studying IUGR, that can be devided
according to the gestational age when IUGR is diag-
nosed: early onset (before 34 weeks) and late onset (after
34 weeks of gestation) IUGR [23, 24]. Equally important,
evidence suggests a sex-specific fetal response to mater-
nal diseases during pregnancy [27]. In the present study,
both gestational age and fetal gender significantly influ-
enced fetal PCSK9 levels. When subgrouping patients
accordingly differences between IUGR and CTRL
remained significant only for male fetuses delivered be-
fore 34 weeks of gestation (early onset IUGR). Yet, the
number of patients in each subgroup is too small to
draw a final conclusion and further studies are neces-
sary. However, our results are in line with the fact that
in response to adverse in-utero insults, male versus fe-
male infants have greater disadvantages in pregnancy
outcome. One explanation may be that the placenta of
the female fetus protects them from adverse prenatal
events [28]. Possibly, however, the growing male fetus
responds differently to sex hormones like estrogens or
progesterons during the in-utero periode. We recently
demonstrated that in addition to reduced LDL-C con-
centrations estrogen and progesterone levels are lower
in IUGR pregnancies [2]. Indeed, estrogen influences
PCSK9 levels and hence cholesterol catabolism [29].
Whether this mechanism selectively affects fetal growth
in the male fetus remains to be clarified.
Our study has some limitations. We cannot exclude
that cord blood and placental parameters within the
CTRL group are biased by factors that may lead to spon-
taneous onset of premature labor. However, gestational
age is one of the main factors affecting cord blood com-
position [7]. Hence, the study groups need to be
controlled for this issue. Due to obvious ethical and
practical reasons fetal blood and placental samples can-
not be obtained in healthy uncomplicated and ongoing
pregnancies antenatally. Moreover, differences in the
treatment regimes between IUGR and CTRL mothers
may have an influence on maternal and/or fetal metabol-
ism. For example, mothers with spontaneous onset of
preterm labor or preterm premature rupture of mem-
branes receive antibiotics and tocolytic agents, while
IUGR mothers do not. Stress also influences lipid
parameters, and fetal distress is a common medical indi-
cation for delivery in patients with IUGR.
Conclusion
In conclusion, the results of the present study suggest
that during pregnancy LDL-C metabolism is under
control of PCSK9 at least in the fetal compartment. In
the maternal compartment PCSK9 was rather mildly
associated, and other mechanisms that control LDL-C
levels remain to be identified. Lower fetal PCSK9 con-
centration levels in IUGR as compared to CTRL might
be the result of altered metabolic adaptation of the fetus
in response to a pathological process during preganancy,
and hence might play a crucal role in the pathophysi-
ology of IUGR. Since we found fetal PCSK9 concentra-
tions being considerably dependent on gestational age
and gender, particular individuals of IUGR might be
identified in the future who benefit from pharmaco-
therapy targeting the fetal PCSK9 pathway. Yet this has
to be elucidated in further studies.
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